4-(Tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide → 4-[8-(4-Methanesulfonyl-phenylamino)-imidazo[1,2-a]pyrazin-5-yl]-benzamide

HRID 1366122

Reaktionsgleichung

Reaktionsgleichung von HRID 1366122
N1(C2C=CC(NC3C4N(C=CN=4)C(C4C=CNC(=O)C=4)=CN=3)=CC=2)CCOCC1.CC1(C)C(C)(C)OB([C:38]2[CH:46]=[CH:45][C:41]([C:42]([NH2:44])=[O:43])=[CH:40][CH:39]=2)O1.Br[C:49]1[N:54]2[CH:55]=[CH:56][N:57]=[C:53]2[C:52]([NH:58][C:59]2[CH:64]=[CH:63][C:62]([S:65]([CH3:68])(=[O:67])=[O:66])=[CH:61][CH:60]=2)=[N:51][CH:50]=1.CC([O-])(C)C.[Na+]>CN(C=O)C.O.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1>[CH3:68][S:65]([C:62]1[CH:63]=[CH:64][C:59]([NH:58][C:52]2[C:53]3[N:54]([CH:55]=[CH:56][N:57]=3)[C:49]([C:38]3[CH:39]=[CH:40][C:41]([C:42]([NH2:44])=[O:43])=[CH:45][CH:46]=3)=[CH:50][N:51]=2)=[CH:60][CH:61]=1)(=[O:66])=[O:67]

Komponenten

8

Edukt 4

HCID 27605884-(Tetramethyl-1,3,2-dioxaborolan-2-yl)benzamideHCID 23676156Sodium t-butoxideHCID 248574474-[8-(4-Morpholin-4-yl-phenylamino)imidazo[1,2-a]pyrazin-5-yl]-1H-pyridin-2-oneHCID 59022984(5-Bromo-imidazo[1,2-a]pyrazin-8-yl)-(4-methanesulfonyl-phenyl)-amine

Produkt 1

HCID 248576534-[8-(4-Methanesulfonyl-phenylamino)-imidazo[1,2-a]pyrazin-5-yl]-benzamide

Reagenzien, Katalysatoren, Lösungsmittel 3

HCID 178418397HCID 178418397, VerbindungKatalysatorHCID 962WaterLösungsmittelHCID 6228DimethylformamideLösungsmittel

Versuchsvorschrift

In the same way as described for Compound 85, step 1, using 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzamide (1.0 g, 6.11 mmol), (5-bromo-imidazo[1,2-a]pyrazin-8-yl)-(4-methanesulfonyl-phenyl)-amine (1.49 g, 4.07 mmol), Pd(PPh3)4 (471 mg, 0.41 mmol) and NaOtBu (1.57 g, 0.82 mmol) in DMF (18 mL) and water (6 mL). The residue is chromatographed on silica gel, eluting with DCM followed by 95:5 DCM:NH3 (7M in MeOH), and the fractions containing the desired product are combined and evaporated to afford a solid, crystallised in ethyl acetate (566 mg, 34%). LCMS: Rt 2.53 min (99%), m/z (APCI) 408 (M+H)+; 1H-NMR (400 MHz, d6-DMSO δ(ppm) 3.21 (3H, s), 7.54 (1H, br s), 7.67 (1H, s), 7.81 (1H, s), 7.86-7.92 (4H, m), 8.09-8.17 (3H, m), 8.21 (1H, br s), 8.41 (2H, d), 10.32 (1H, s).

Aufarbeitung

  1. customThe residue is chromatographed on silica gel
  2. washeluting with DCM
  3. additionNH3 (7M in MeOH), and the fractions containing the desired product
  4. customevaporated
  5. customto afford a solid
  6. customcrystallised in ethyl acetate (566 mg, 34%)

Quellen und Nachweise

ORD-Eintrag
ord-851af5bc762143cd9f6b29238e7a6800
Quelldatensatz
uspto-grants-2011_02
Patentnummer
US07893058B2

Verknüpfte Notizen

Wird geladen…